Stock MLYS MINERALYS THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Mineralys Therapeutics, Inc.

Equities

MLYS

US6031701013

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
12.77 USD +2.82% Intraday chart for Mineralys Therapeutics, Inc. +4.67% +48.49%
May. 16 Transcript : Mineralys Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 05:01 PM
May. 09 Transcript : Mineralys Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Mineralys Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Mineralys Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Mineralys Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
North American Morning Briefing : Investors -2-
DJ
Mineralys Therapeutics, Inc. Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension
CI
Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023
CI
Mineralys Therapeutics, Inc Presents Data from the Target-HTN Phase 2 Trial That Further Defines an Endotype-Specific Targeted Approach for Treating Uncontrolled or Resistant Hypertension with Lorundrostat
CI
Mineralys Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Mineralys Therapeutics, Inc. Presents New Post-Hoc Analysis from Target-HTN Phase 2 Trial of Lorundrostat in Late-Breaking Poster Session at ASN Kidney Week 2023 Meeting
CI
Mineralys Therapeutics, Inc. Announces Jama Publication of Full Target-HTN Phase 2 Trial Results for Lorundrostat in Uncontrolled and Treatment-Resistant Hypertension
CI
Mineralys Therapeutics Presents Target-HTN Phase 2 Trial Results in Late-Breaking Science Session At 2023 Aha Hypertension Scientific Sessions
CI
Mineralys Therapeutics, Inc. Doses the First Patient in the Advanceance-Htn Pivotal Trial
CI
Mineralys Therapeutics Q4 Loss Widens; Shares Decline After-Hours
MT
Mineralys Therapeutics Reports Positive Lorundrostat Results in Reducing Hypertension in Phase 2 Trial
MT
Mineralys Therapeutics Presents Positive Lorundrostat Results from the Phase 2 Target-HTN Trial at ACC.23/WCC
CI
Mineralys Therapeutics Prices IPO at $16 per Share
MT
Mineralys Therapeutics, Inc. has completed an IPO in the amount of $192 million.
CI
Mineralys Therapeutics, Inc. has filed an IPO in the amount of $100 million.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MLYS Stock
  4. News Mineralys Therapeutics, Inc.
  5. Highlights